



Bwrdd Iechyd Prifysgol Bae Abertawe Swansea Bay University Health Board



Meeting Date	24 <sup>th</sup> August 2	2021	Agenda Item	3.1	
Report Title	Financial Rep	ort – Period 4 20	)21/22	·	
Report Author	Samantha Lewis, Deputy Director of Finance				
Report Sponsor	Darren Griffiths, Director of Finance and Performance				
Presented by	Darren Griffiths, Director of Finance and Performance				
Freedom of	Open				
Information					
Purpose of the	The report advises the Performance and Finance				
Report	Committee of the Health Board financial position for Period				
	4 (July) 2021/22 and sets out the current forecast revenue				
	year end outto	urn.			
			·		
Key Issues		rites the Performa			
	to note the detailed analysis of the financial position for				
	Period 4 (July	<i>(</i> ) 2021/22.			
	The report in	cludes an analys	ic of the COV/II		
		ne forecast year			
		•	•	USILIOIT DASEU	
	on current planning assumptions.				
	Risks have be	en updated.			
Specific Action	Information	Discussion	Assurance	Approval	
Required			$\boxtimes$		
(please choose					
one only)					
Recommendations	Members are asked to:				
		askeu iu.			
1		he agreed 2021/2			
	CONSIE	he agreed 2021/2 DER and comme	nt upon the Boa	rd's financial	
	CONSIE     performa	he agreed 2021/2 <b>DER</b> and comme ance for Perio	nt upon the Boa	rd's financial	
	CONSIE     performa     particula	he agreed 2021/2 <b>DER</b> and comme ance for Perio ar:	nt upon the Boa od 4 (July)	rd's financial 2021/22, in	
	<ul> <li>CONSIE performa particula</li> <li>the</li> </ul>	he agreed 2021/2 <b>DER</b> and comme ance for Perio ar: revenue outturn	nt upon the Boa od 4 (July)	rd's financial 2021/22, in	
	<ul> <li>CONSIE performa particula</li> <li>the and</li> </ul>	he agreed 2021/2 <b>DER</b> and comme ance for Peric ar: revenue outturn	nt upon the Boa od 4 (July) 1 position of £8.0	rd's financial 2021/22, in 54m deficit;	
	<ul> <li>CONSIE performa particula</li> <li>the and</li> <li>the</li> </ul>	he agreed 2021/2 DER and comme ance for Perio ar: revenue outturn adjusted year	nt upon the Boa od 4 (July) 1 position of £8.0	rd's financial 2021/22, in 54m deficit;	
	<ul> <li>CONSIE performaticula</li> <li>the and</li> <li>the £24</li> </ul>	he agreed 2021/2 DER and comme ance for Peric ar: revenue outturn adjusted year .405m.	nt upon the Boa od 4 (July) position of £8.0 -end forecast	rd's financial 2021/22, in 54m deficit; deficit of	
	<ul> <li>CONSIE performs particula</li> <li>the and</li> <li>the £24</li> <li>NOTE the figure of t</li></ul>	he agreed 2021/2 DER and comme ance for Perio ar: revenue outturn adjusted year .405m. ne actions to ens	nt upon the Boa od 4 (July) position of £8.0 -end forecast	rd's financial 2021/22, in 54m deficit; deficit of	
	<ul> <li>CONSIE performation particula</li> <li>the and</li> <li>the £24</li> <li>NOTE the forecast</li> </ul>	he agreed 2021/2 DER and commendance for Periodar: revenue outturn adjusted year .405m. he actions to ens	nt upon the Boa od 4 (July) position of £8.0 -end forecast ure delivery of t	rd's financial 2021/22, in 54m deficit; deficit of he financial	
	<ul> <li>CONSIE performation particula</li> <li>the and</li> <li>the £24</li> <li>NOTE the forecast</li> <li>AGREE</li> </ul>	he agreed 2021/2 DER and comme ance for Perio ar: revenue outturn adjusted year .405m. ne actions to ens	nt upon the Boa od 4 (July) position of £8.0 -end forecast ure delivery of t or risks 73 and	rd's financial 2021/22, in 54m deficit; deficit of he financial 79	

# FINANCIAL REPORT – PERIOD 4

# 1. INTRODUCTION

The report provides the Performance and Finance Committee with an account of the period 4 revenue position

The report informs the Performance and Finance Committee that the Period 4 (July 2021) revenue financial position is an overspend of £8.054m and invites the committee to note the detailed analysis of the Period 4 (July 2021) revenue financial position.

# 2. BACKGROUND

The Health Board agreed the Annual Plan for 2021/22 at its meeting on 23<sup>rd</sup> June 2021, having approved the draft annual plan in March 2021. This included a financial plan which reflected a £42.077m opening underlying deficit and indicated that in-year cost pressures and investment commitments could be met by WG allocation uplift and planned savings. The Health Board plan therefore produces a £42.077m forecast deficit.

	2021-22 Plan Update £m
20/21 Core Underlying Position	24.405
20/21 Savings COVID impact	17.672
20/21 Underlying Position	42.077
Cost pressures	25.600
WG Allocation	-15.100
Investment Commitments	8.500
Planned Savings	-27.700
Investments to enable Savings	8.700
Forecast Position	42.077

The savings requirement for 2021/22 of £27.7m is a gross saving position, which recognises and allows for the investments to support the delivery of efficiency opportunities.

The Health Board is also anticipating around £120m of COVID funding for this financial year, this is based on assumed costs for 12 months. This £120m includes non-recurrent funding to mitigate the COVID impact on 2020/21 savings. This reduces the forecast deficit to £24.405m.

# 3. FINANCIAL IMPLICATIONS

### 3.1 Revenue Position

# 3.1.1 Summary Revenue Position

The Health Board deficit plan is being held within the Corporate Plan. Based on the adjusted forecast deficit, there would be a planned  $\pounds 2.034m$  overspend each month.

The unmet savings targets from 2020/21 have been removed from the Service Group and Corporate Directorates. COVID funding has been allocated to meet COVID costs. All Service Groups and Corporate Directorates are therefore being managed against an expectation of breakeven.

The period 4 reported in-month position was an overspend of  $\pounds$ 1.973m and  $\pounds$ 8.054m cumulatively. The cumulative position should be compared with the planned deficit of  $\pounds$ 8.135m. The cumulative position is  $\pounds$ 0.081m below the forecast position.

	Budget	Actual	Variance	Budget	Actual	Variance
	In Month	In Month	In Month	Cumulative	Cumulative	Cumulative
	£000	£000	£000	£000	£000	£000
Income	- 23,168	- 22,977	191	- 95,036	- 94,045	991
Pay	52,997	51,543	- 1,454	204,607	202,440	- 2,167
Non-Pay	56,374	57,577	1,203	219,600	220,696	1,096
Delegated Position	86,203	86,143	- 60	329,171	329,091	- 80
Corporate Plan	- 2,033		2,033	- 8,134		8,134
Total Position	84,170	86,143	1,973	321,037	329,091	8,054

### 3.1.2 Income

Income budgets have reported an under-achievement of £0.991m.

The key areas of under-achievement are dental, catering, rental and other patient related charges. The LTA and SLA block arrangements are expected to remain in place for the rest of this financial year, however this is not yet formally agreed. The inflationary and pre-pandemic performance impacts are being reviewed to ensure all are appropriately reflected.

The current income position is being supported by around £0.6m per month of COVID sustainability response funding. This support will be reviewed through monthly performance meetings to consider the recovery mechanisms and potential longer term impacts.

### 3.1.3 Pay

Pay budgets have reported a £2.167m underspend for the first four months of the financial year.

This month has seen high level of underspend which is in part due to backdated funding support for COVID response, where costs have been identified linked to staff unavailability and also funding received which supports costs already incurred.

Whilst there were pressures in early months, significant improvements have been made in robust roster management and mitigating costs, which has resulted in an improved level of performance. Medical staff costs continue to exceed budgets and Service Group Medical Directors have been asked to review the cause, impact and mitigating actions as a matter of urgency.

Around £1m of COVID funding has been issued to support increased pay costs in the first four months, excluding funding for vaccination, TTP and cleaning standards. This significant cost is supporting changed service models and requirements, surge capacity and other additional support. The management of ongoing legacy of costs will be crucial in the development of a sustainable financial model going forward.

## 3.1.4 Non Pay

Non-pay budgets have reported an overspend of £1.1m for the first four months. The key drivers of the overspend being ChC costs within MH and LD, which are partially offset by workforce underspends and reducing levels of underspend being reported particularly within clinical consumables budgets. This reduction in clinical consumables underspend reflects increasing levels of activity, particularly emergency activity and more specialist work, which require high cost clinical consumables.

The level of COVID support to general non-pay is around £3m for the first quarter. In addition, around £2m funding support has been provided to Primary Care Prescribing to support the increased costs being experienced.

## 3.1.5 Savings and Recovery Challenge

The Health Board plan includes a gross savings requirement £27.7m, this supports the investment to enable efficiency opportunities to be released.

To date the Health Board has identified £26.1m of green and amber savings, with a further £3.3m of red schemes which are being developed.

Green schemes have increased by £0.6m in month, which is positive progress.

The focus to the end of Quarter 2 must be to further risk assess the amber and red schemes to provide assurance of delivery or mitigating further schemes and actions. This is essential both for this year but also for recurrent position as the full year recurrent impact of the amber and red schemes are £12.5m of the identified £29m.

Work has commenced to identify plans and opportunities to deliver 50% of next years anticipated savings requirement by the end of September. This is an ambitious ask but early identification of opportunities will be crucial for the financial Recovery and Sustainability of the Health Board.

### 4. COVID-19

The Health Board is assuming around £118m of additional funding to support COVID response and recovery. This is based on current experience and planning assumptions and will be refined during the forthcoming months as guidance and further modelling is amended. The table below provides a summary of the additional funding anticipated.

	Anticipated COVID
	Funding £m
General	43.705
PPE	5.136
Care Homes	3.166
Cleaning Standards	2.304
Extended Flu	1.160
Vaccinations	13.266
Trace	12.500
Testing	2.767
Long COVID	0.635
COVID Response	84.639
COVID Recovery	16.243
20/21 Savings Impact	17.672
Total Allocation	118.554

The system of financial management for 2021/22 will be to allocate COVID response and recovery funding to meet the areas where expenditure is incurred. This will allow for more transparent management of budget variance and will support the required levels of accountability required as the Health Board continues its response and recovery activities.

It is expected that the any COVID funding provided will be fully deployed.

The COVID recovery funding included reflects the first tranche of resource anticipated which was allocated by Welsh Government in May 2021. The primary focus of this first wave of funding is on increasing capacity to improve access for patients across cancer services, outpatients, diagnostics and surgical treatment. Costs will be incurred in line with agreed funding.

Further proposals are being developed to further enhance and support recovery. These costs will only be incurred in line with agreed funding.

# 5. FORECAST POSITION

The Health Board submitted its final annual plan on 30<sup>th</sup> June, following Board approval on 23<sup>rd</sup> June. The final plan produces a £42m deficit, which has been reduced to £24.4m following the application of anticipated non-recurrent funding to support the COVID impact on 2020/21 savings delivery.

The Health Board is currently on target to deliver the £24.4m forecast. This is being monitored closely to reflect risks and opportunities as they arise. At this stage there are no further recurrent pressures or opportunities identified which would impact on the £42m recurrent deficit.

A full review of investments, savings, risks and opportunities will be undertaken for the end of Quarter 2 to support the assurance of the forecast.

# 6. OPPORTUNITIES AND RISKS

Through the regular review of opportunities and risks and continuing discussions with WG and following the revision of the forecast, the Health Board is endeavouring to manage opportunities and risks that may arise within the overall forecast position.

Any significant changes to income or expenditure assumptions will be highlighted to the Performance and Finance Committee.

# 7. RISK ASSESSMENT

There are currently two Board level financial risks: -

- Residual Cost Base (risk 73): There is a potential for a residual cost base increase post COVID-19 as a result of changes to service delivery models and ways of working Risk Rated 20. It is proposed that this risk remains unchanged
- Resource required lower than health board recovery plan ambition (risk • 79): The Performance and Finance Committee agreed that this risk be established for 2021/22. During 2020/21 the COVID-19 pandemic impacted services in many different ways. Of particular concern has been the impact on access to services, particularly outpatients, diagnostic tests, elective surgery and therapy services. The recovery of access times to prepandemic levels will require a significant amount of human, estates and financial resource to support it. There is potential for the scale of ambition that the Health Board has in terms of access recovery will be unaffordable in context of the current financial plan. The risk has been submitted as severe impact (5) but moderate likelihood. Since drafting the risk the Health Board has been notified of a first tranche of funding of £16.243m to address this. The risk will be reviewed in light of this new information. Unchanged until the outcome of the Health Board's further tranche of recovery bids to Welsh Government is known.
- Availability of capital. Risk 72 was closed towards the end of 2020/21 as it became clear that the Health Board's immediate capital demands would be met within a balanced Capital Resource Limit. Capital has been identified as a scarce resource again in 2021/22 and with limited national capital the Health Board's discretionary plan remains balanced, but does not fully meet the Health Board's immediate need. It is therefore proposed to Committee that this risk now be re-opened and scored at 15 (high consequence/medium likelihood) to capture this risk whilst further discussions with Welsh Government are held.

# 8. ACTIONS AND NEXT STEPS

The new financial year will see the following actions:

### In relation to month 4 position

 Urgent review of medical cost pressures and mitigating actions by 31<sup>st</sup> August 2021 (Service Group Medical Directors).

- Nurse Director and Medical Director to update on variable pay reduction plans by 31<sup>st</sup> August 2021.
- Review COVID response cost, exit strategies and assess potential ongoing impacts month 5 and 6 finance review meetings.
- The preparation of a CHC plan for Mental Health and Learning Disabilities services for consideration by Management Board by end of September.
- Ongoing identification of savings pipeline and delivery of planned savings, including 50% of 2022/23 anticipated savings target by end of September (All).
- Full review of investments, savings, risks and opportunities to be completed for end of Quarter 2.

# In-year actions

- Broader monthly performance reviews to replace financial reviews, this will enable greater triangulation of service, workforce and financial performance.
- Increased focus on compliance with key control measures.
- Implementation of the Performance Framework for escalation.
- Implementation of Business Case Assurance Group to support the scrutiny of business cases.
- Implementation of a revised system of internal financial control.
- Enhanced PMO function to support service model changes and realisation of benefits.
- Development of Savings Delivery team to support monitoring, identification and implementation of savings.

# 9. **RECOMMENDATION**

Members are asked to: -

- **NOTE** the agreed 2021/22 financial plan.
- **CONSIDER** and comment upon the Board's financial performance for Period 4 (July) 2021/22, in particular:
  - the revenue outturn position of £8.054m deficit; and
  - the year-end forecast deficit of £24.405m.
- **NOTE** the actions to manage the financial position within the forecast.
- AGREE the risk scores for risks 73 and 79
- AGREE the re-opening of risk 72 on capital availability

Governance ar	nd Assurance					
Link to		promoting and				
Enabling	empowering people to live well in resilient communities					
Objectives	Partnerships for Improving Health and Wellbeing					
(please choose)	Co-Production and Health Literacy					
	Digitally Enabled Health and Wellbeing					
	Deliver better care through excellent health and care services achieving the outcomes that matter most to people					
	Best Value Outcomes and High Quality Care	$\boxtimes$				
	Partnerships for Care	$\boxtimes$				
	Excellent Staff					
	Digitally Enabled Care					
	Outstanding Research, Innovation, Education and Learning					
Health and Ca	re Standards	·				
(please choose)	Staying Healthy					
	Safe Care					
	Effective Care					
	Dignified Care					
	Timely Care					
	Individual Care					
	Staff and Resources	$\boxtimes$				
Quality, Safety	and Patient Experience					
Financial Gover	mance supports quality, safety and patient experience.					
Financial Impli	cations					
The Board is re the impact of C	porting a £24.4m forecast year-end deficit financial outt OVID-19.	urn prior to				
Legal Implicati	ons (including equality and diversity assessment)					
	for the Committee to be aware of.					
Staffing Implic	ations					
No implications	for the Committee to be aware of.					
	plications (including the impact of the Well-being of Vales) Act 2015)	Future				
	for the Committee to be aware of.					
Report History	The Committee receives an update on the finan at every meeting	icial position				
Appendices	Appendix 1 – Month 4 Financial Report					